Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00468182 · ClinicalTrials.gov registry record
Modulation of Plasmacytoid Dendritic Cell Function in Multiple Sclerosis
A clinical trial, sponsored by Rutgers, The State University of New Jersey.
- Completed
- Registry status
- 24
- Enrollment target
NCT00468182: Completed study, sponsored by Rutgers, The State University of New Jersey.
NCT00468182 is a clinical trial that has completed, run by Rutgers, The State University of New Jersey. The registered enrollment target is 24 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00468182 has completed, sponsored by Rutgers, The State University of New Jersey.
- COMPLETED
- Registry status
- 24 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether interferon-beta impairs the ability of plasmacytoid dendritic cells to promote pathogenic immune responses in patients with multiple sclerosis.
Primary Outcome
Gene expression is tested in pDCs separetd from peripheral blood of human subjects at baseline and at 12 weeks
Interventions
- DRUG Interferon-beta 1b (Betaseron)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2007-04 |
| Est. Completion | 2011-12 |
What the finished NCT00468182 record still lists
NCT00468182 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 24 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Interferon-beta 1b (Betaseron) is the first listed.
NCT00468182 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00468182 about?
NCT00468182 is a clinical study titled "Modulation of Plasmacytoid Dendritic Cell Function in Multiple Sclerosis". The purpose of this study is to determine whether interferon-beta impairs the ability of plasmacytoid dendritic cells to promote pathogenic immune responses in patients with multiple sclerosis.
What is the current status of trial NCT00468182?
This trial is currently completed. The enrollment target is 24 participants. The study started on 2007-04. Estimated completion is 2011-12.
What interventions are being tested in trial NCT00468182?
The interventions under investigation include: Interferon-beta 1b (Betaseron) (DRUG).
Who is sponsoring clinical trial NCT00468182?
This trial is sponsored by Rutgers, The State University of New Jersey, which has 413 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia